Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of Trelegy Ellipta versus FF/VI in adolescents with inadequately controlled asthma
MOH_2024-11-25_013751Phase 3Recruiting
- Sponsor
- GSK
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone and fluticasone propionate + vilanterol in asthma (2 arms), sponsored by GSK. Primary endpoint: Primary efficacy endpoint. Started Nov 2024; status: recruiting.
02
Drugs
fluticasonefluticasone propionate + vilanterol
03
Conditions
asthma
Beyond the preview
Go deeper on MOH_2024-11-25_013751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-11-25_013751.